136 related articles for article (PubMed ID: 37877337)
1. Qiliqiangxin: A multifaceted holistic treatment for heart failure or a pharmacological probe for the identification of cardioprotective mechanisms?
Packer M
Eur J Heart Fail; 2023 Dec; 25(12):2130-2143. PubMed ID: 37877337
[TBL] [Abstract][Full Text] [Related]
2. Qiliqiangxin Attenuates Oxidative Stress-Induced Mitochondrion-Dependent Apoptosis in Cardiomyocytes via PI3K/AKT/GSK3β Signaling Pathway.
Zhao Q; Li H; Chang L; Wei C; Yin Y; Bei H; Wang Z; Liang J; Wu Y
Biol Pharm Bull; 2019 Aug; 42(8):1310-1321. PubMed ID: 31142701
[TBL] [Abstract][Full Text] [Related]
3. Foetal recapitulation of nutrient surplus signalling by O-GlcNAcylation and the failing heart.
Packer M
Eur J Heart Fail; 2023 Aug; 25(8):1199-1212. PubMed ID: 37434410
[TBL] [Abstract][Full Text] [Related]
4. Cardioprotective Effects of Sirtuin-1 and Its Downstream Effectors: Potential Role in Mediating the Heart Failure Benefits of SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors.
Packer M
Circ Heart Fail; 2020 Sep; 13(9):e007197. PubMed ID: 32894987
[TBL] [Abstract][Full Text] [Related]
5. Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis.
Packer M
Circulation; 2022 Nov; 146(18):1383-1405. PubMed ID: 36315602
[TBL] [Abstract][Full Text] [Related]
6. The diabetes medication canagliflozin promotes mitochondrial remodelling of adipocyte via the AMPK-Sirt1-Pgc-1α signalling pathway.
Yang X; Liu Q; Li Y; Tang Q; Wu T; Chen L; Pu S; Zhao Y; Zhang G; Huang C; Zhang J; Zhang Z; Huang Y; Zou M; Shi X; Jiang W; Wang R; He J
Adipocyte; 2020 Dec; 9(1):484-494. PubMed ID: 32835596
[TBL] [Abstract][Full Text] [Related]
7. Longevity genes, cardiac ageing, and the pathogenesis of cardiomyopathy: implications for understanding the effects of current and future treatments for heart failure.
Packer M
Eur Heart J; 2020 Oct; 41(39):3856-3861. PubMed ID: 32460327
[TBL] [Abstract][Full Text] [Related]
8. Traditional Chinese medicine Qiliqiangxin attenuates phenylephrine-induced cardiac hypertrophy via upregulating PPARγ and PGC-1α.
Gao RR; Wu XD; Jiang HM; Zhu YJ; Zhou YL; Zhang HF; Yao WM; Li YQ; Li XL
Ann Transl Med; 2018 Apr; 6(8):153. PubMed ID: 29862242
[TBL] [Abstract][Full Text] [Related]
9. Research on Q-markers of Qiliqiangxin capsule for chronic heart failure treatment based on pharmacokinetics and pharmacodynamics association.
Zhang F; Zhang Y; Li X; Zhang S; Zhu M; Du W; Xiao X
Phytomedicine; 2018 May; 44():220-230. PubMed ID: 29699844
[TBL] [Abstract][Full Text] [Related]
10. Qili Qiangxin, a compound herbal medicine formula, alleviates hypoxia-reoxygenation-induced apoptotic and autophagic cell death via suppression of ROS/AMPK/mTOR pathway in vitro.
Fan CL; Cai WJ; Ye MN; Chen M; Dai Y
J Integr Med; 2022 Jul; 20(4):365-375. PubMed ID: 35534381
[TBL] [Abstract][Full Text] [Related]
11. The Metabolic Effects of Traditional Chinese Medication Qiliqiangxin on H9C2 Cardiomyocytes.
Lin S; Wu X; Tao L; Bei Y; Zhang H; Zhou Y; Shen S; Xiao J; Li X
Cell Physiol Biochem; 2015; 37(6):2246-56. PubMed ID: 26618786
[TBL] [Abstract][Full Text] [Related]
12. Traditional Chinese Medication Qiliqiangxin Protects Against Cardiac Remodeling and Dysfunction in Spontaneously Hypertensive Rats.
Wang H; Zhang X; Yu P; Zhou Q; Zhang J; Zhang H; Zhu H; Zhang C; Yao W; Che L; Xu J; Bei Y; Li X
Int J Med Sci; 2017; 14(5):506-514. PubMed ID: 28539827
[TBL] [Abstract][Full Text] [Related]
13. Role of ketogenic starvation sensors in mediating the renal protective effects of SGLT2 inhibitors in type 2 diabetes.
Packer M
J Diabetes Complications; 2020 Sep; 34(9):107647. PubMed ID: 32534886
[TBL] [Abstract][Full Text] [Related]
14. Silent information regulator 1 ameliorates oxidative stress injury via PGC-1α/PPARγ-Nrf2 pathway after ischemic stroke in rat.
Zhou Y; Peng L; Li Y; Zhao Y
Brain Res Bull; 2022 Jan; 178():37-48. PubMed ID: 34774993
[TBL] [Abstract][Full Text] [Related]
15. Protective effect of Xinmai'an tablets via mediation of the AMPK/SIRT1/PGC-1α signaling pathway on myocardial ischemia-reperfusion injury in rats.
Zhang W; Chen R; Xu K; Guo H; Li C; Sun X
Phytomedicine; 2023 Nov; 120():155034. PubMed ID: 37611465
[TBL] [Abstract][Full Text] [Related]
16. The discovery of Q-markers of Qiliqiangxin Capsule, a traditional Chinese medicine prescription in the treatment of chronic heart failure, based on a novel strategy of multi-dimensional "radar chart" mode evaluation.
He L; Liu Y; Yang K; Zou Z; Fan C; Yao Z; Dai Y; Li K; Chen J; Yao X
Phytomedicine; 2021 Feb; 82():153443. PubMed ID: 33429210
[TBL] [Abstract][Full Text] [Related]
17. Traditional Chinese Medication Qiliqiangxin attenuates cardiac remodeling after acute myocardial infarction in mice.
Tao L; Shen S; Fu S; Fang H; Wang X; Das S; Sluijter JP; Rosenzweig A; Zhou Y; Kong X; Xiao J; Li X
Sci Rep; 2015 Feb; 5():8374. PubMed ID: 25669146
[TBL] [Abstract][Full Text] [Related]
18. Qiliqiangxin protects against anoxic injury in cardiac microvascular endothelial cells via NRG-1/ErbB-PI3K/Akt/mTOR pathway.
Wang J; Zhou J; Wang Y; Yang C; Fu M; Zhang J; Han X; Li Z; Hu K; Ge J
J Cell Mol Med; 2017 Sep; 21(9):1905-1914. PubMed ID: 28271613
[TBL] [Abstract][Full Text] [Related]
19. Study protocol for a randomized controlled trial: Qiliqiangxin in heart failUre: assESsment of reduction in morTality (QUEST).
Yao W; Cheang I; Liao S; Zhou Y; Zhou F; Xu D; Jia Z; Chang L; Zhang H; Li X
BMC Complement Med Ther; 2020 Feb; 20(1):38. PubMed ID: 32024496
[TBL] [Abstract][Full Text] [Related]
20. Danqi Tablet () Regulates Energy Metabolism in Ischemic Heart Rat Model through AMPK/SIRT1-PGC-1α Pathway.
Meng H; Wang QY; Li N; He H; Lu WJ; Wang QX; Sun XQ; Jiao SH; Wang Y; Tu PF
Chin J Integr Med; 2021 Aug; 27(8):597-603. PubMed ID: 31144160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
